← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-12 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
AntibodystaleMerck Sharp & Dohme LLCPhase 2

Vibostolimab (Vibostolimab)

Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#항체#면역항체+3
효능 ORR 71.7%임상시험 19상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 3

Volrustomig (Volrustomig)

Metastatic Non-small Cell Lung Cancer · Endometrial Cancer

#EndometrialCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 19상태 RECRUITING
AntibodyRochePreclinical

atezolizumab (Tecentriq, Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Preclinical#항체#면역항체+2
효능 ORR 88.7%임상시험 18상태 RECRUITING
ADCBiologicstaleSichuan Baili Pharmaceutical Co…Phase 3

BL-M07D1 (BL-M07D1)

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 18상태 RECRUITING
AntibodystaleRochePhase 1

Bevacizumab-IRDye800CW (Bevacizumab-IRDye800CW)

Adenomatous Polyposis Coli · Esophageal Cancer

#EsophagealCancer#Antibody#Phase1#항체#면역항체+3
임상시험 18상태 ACTIVE
AntibodystaleNeovii BiotechPhase 2

Catumaxomab (Catumaxomab)

Gastric Cancer; Gastric Adenocarcinoma · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+3
임상시험 18상태 ACTIVE
AntibodystaleMerck Sharp & Dohme LLCPhase 2

Favezelimab (Favezelimab)

Neoplasm Metastasis · Neoplasms

#Neoplasms#Antibody#Phase2#항체#면역항체+3
효능 ORR 6.8%임상시험 18상태 DISCONTINUED
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Favezelimab/Pembrolizumab)

Neoplasm Metastasis · Neoplasms

#Neoplasms#Antibody#Phase2#항체#면역항체+3
효능 ORR 6.8%임상시험 18상태 ACTIVE
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Ifinatamab deruxtecan (Ifinatamab deruxtecan)

Prostate Cancer; Prostatic Neoplasms · Small Cell Lung Cancer

#SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
임상시험 18상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

MK-1084 (MK-1084)

Malignant Neoplasm · Lung Neoplasm Malignant

#LungNeoplasmMalignant#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 18상태 RECRUITING
AntibodystaleRegeneron PharmaceuticalsPhase 3

Odronextamab (Odronextamab)

Relapsed/Refractory Aggressive B-Cell Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#항체#면역항체+4
임상시험 18상태 RECRUITING
ADCBiologicstaleFondazione per la Medicina Pers…Phase 3

Pralsetinib (Pralsetinib)

Breast Cancer; Gastrointestinal Cancer · Solid Tumor

#SolidTumor#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 53.8%임상시험 18상태 ACTIVE
AntibodystaleRochePhase 3

Rituximab and Hyaluronidase Human (Rituximab and Hyaluronidase Human)

Richter Syndrome; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase3#항체#면역항체+4
효능 ORR 9%임상시험 18상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 2

AZD5305 (Saruparib, Saruparib (AZD5305))

Ovarian Cancer; Lung Adenocarcinoma · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 18상태 RECRUITING
ADCBiologicstaleBioMed Valley Discoveries, IncPhase 2

Ulixertinib (Ulixertinib)

Metastatic Colorectal Cancer · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 2%임상시험 18상태 RECRUITING
AntibodystaleBristol-Myers SquibbPhase 2

Urelumab (Urelumab)

Pancreatic Cancer · Malignant Tumors

#MalignantTumors#Antibody#Phase2#항체#면역항체+3
효능 ORR 5%임상시험 18상태 RECRUITING
ADCBiologicstaleMabwell (Shanghai) Bioscience C…Phase 3

9MW2821 (9MW2821)

Locally Advanced or Metastatic Triple-negative Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 17상태 RECRUITING
ADCBiologicstaleDanish Breast Cancer Cooperativ…Phase 3

Abemaciclib with ET (Abemaciclib with ET)

Metastatic Breast Cancer; ER-positive Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 0%임상시험 17상태 DISCONTINUED
ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Tislelizumab)

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 17상태 ACTIVE
ADCBiologicstaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Tislelizumab)

Breast Cancer; Neoadjuvant Therapy · Breast Cancer

#BreastCancer#ADC#Approved#항체약물접합체#antibody-drug-conjugate+2
임상시험 17상태 ACTIVE

41 / 209 페이지

← 이전다음 →